We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 16, 2005
Last Update Posted: February 20, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Robert Lowsky, Stanford University
To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GV/HD) occurs.

Condition Intervention Phase
Blood Cancer Leukemia Drug: cyclosporine Drug: Thymoglobulin Drug: mycophenolate mofetil Drug: g-csf Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies

Further study details as provided by Robert Lowsky, Stanford University:

Primary Outcome Measures:
  • To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GV/HD) occurs.

Secondary Outcome Measures:
  • To evaluate the incidence and extent of chronic GVHD.
  • To document the quantitative and qualitative reconstitution of the immune system including T cell subsets, NK cells and B cells.
  • To evaluate the rate of relapse, overall and event-free survival and transplant related mortality rate.
  • To evaluate the kinetics of donor hematopoietic cell engraftment and chimerism.

Enrollment: 299
Study Start Date: March 2003
Study Completion Date: January 2015
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Non-myeloablative transplantation Drug: cyclosporine
3-5 mg/kg BID; IV or oral
Other Names:
  • cyclosporin
  • cyclosporin A
Drug: Thymoglobulin
7.5-10 mg/kg; IV
Other Name: Anti-thymocyte globulin
Drug: mycophenolate mofetil
15 mg/kg BID or Q 8 hours
Other Names:
  • MMF
  • CellCept
Drug: g-csf
16 mcg/kg; SQ
Other Names:
  • Granulocyte colony-stimulating factor
  • gcsf
  • colony-stimulating factor 3
  • csf 3


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

(A) Any patient with one of the following hematolymphoid malignancies or syndromes in whom allogeneic NST is warranted. Specific disease categories include: indolent advanced stage Non-Hodgkin Lymphomas, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Disease, Acute Leukemias in complete remission, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, and, Myelodysplastic and Myeloproliferative Syndromes. Patients with other selected malignancies/disorders may also be considered but must be approved by the transplant team and the Principal Investigator.

(B) Patient age > 50 years, or for patients <50 years of age but because of pre-existing medical conditions or prior therapy are considered to be at high risk for regimen-related toxicity associated with conventional myeloablative transplants.

(C) A fully HLA-identical sibling or matched unrelated donor is available. Patients with one antigen mismatched donors can be considered but only after discussion with the transplant team and the Principal Investigator.

(D) Patient must be competent to give consent.

Exclusion Criteria:

(A) Patients with progressive hematolymphoid malignancies despite conventional therapies, or acute leukemias not in complete remission.

(B) Uncontrolled CNS involvement with disease

(C) Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment

(D) Females who are pregnant

(E) Organ dysfunction defined as follows:

  • Cardiac function: ejection fraction <30% or uncontrolled cardiac failure
  • Pulmonary: DLCO <40% predicted
  • Liver function abnormalities: elevation of bilirubin to > 3 mg/dl and/or transaminases >4x the upper limit of normal
  • Renal: creatinine clearance <50 cc/min (24 hour urine collection)

(F) Karnofsky performance score < 60%

(G) Patients with poorly controlled hypertension on multiple antihypertensives

(H) Documented fungal disease that is progressive despite treatment

(I) Viral infections: HIV positive patients. Hepatitis B and C positive patients will be evaluated on a case by case basis

(J) Psychiatric disorders or psychosocial problems which in the opinion of the primary physician or Principal Investigator would place the patient at unacceptable risk from this regimen.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00185640

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Robert Lowsky Stanford University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robert Lowsky, Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT00185640     History of Changes
Obsolete Identifiers: NCT00186615
Other Study ID Numbers: BMT153
78998 ( Other Identifier: Stanford University Alternate IRB Approval Number )
BMT153 ( Other Identifier: Stanford University )
11960 ( Other Identifier: Stanford IRB )
First Submitted: September 12, 2005
First Posted: September 16, 2005
Last Update Posted: February 20, 2015
Last Verified: February 2015

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases
Mycophenolate mofetil
Mycophenolic Acid
Antilymphocyte Serum
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Antibiotics, Antineoplastic
Antineoplastic Agents
Adjuvants, Immunologic

To Top